- Home
- RDIB vs PLX Comparison
RDIB vs PLX Comparison
Compare RDIB & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDIB | PLX |
|---|---|---|
| Founded | 1937 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.2M | 207.1M |
| IPO Year | 1994 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RDIB | PLX |
|---|---|---|
| Price | $8.55 | $2.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 754.6K |
| Earning Date | 11-13-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $202,988,000.00 | $52,744,000.00 |
| Revenue This Year | $15.10 | $55.77 |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | $9.61 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.00 | $1.65 |
| 52 Week High | $24.00 | $3.19 |
Technical Indicators
Market Signals| Indicator | RDIB | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.29 | 47.34 |
| Support Level | $8.21 | $2.21 |
| Resistance Level | $10.22 | $2.75 |
| Average True Range (ATR) | 0.57 | 0.10 |
| MACD | -0.30 | -0.00 |
| Stochastic Oscillator | 30.49 | 41.27 |
Price Performance
Historical ComparisonAbout RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.